Clinical Trial
Effects of the Medicare Alzheimer's disease demonstration on Medicare expenditures
Affiliations
- PMID: 11482124
- PMCID: PMC4194605
Item in Clipboard
Clinical Trial
Effects of the Medicare Alzheimer's disease demonstration on Medicare expenditures
Health Care Financ Rev.
1999 Summer.
Abstract
Applicants were randomized either into a group with a limited Medicare community care service benefit and case management or into a control group receiving their regular medical care. Analyses assess whether or not community care management affected health care use. A tendency toward reduced expenditures was observed for the treatment group, combining all demonstration sites, and when observing each separately. These differences were or approached statistical significance in two sites for Medicare Part A and Parts A and B expenditures averaged over 3 years. Expenditure reductions approached budget neutrality with program costs in two sites.
References
-
- Anderson R, Newman J. Societal and Individual Determinants of Medical Care Utilization in the U. S. Milbank Memorial Fund Quarterly Health and Society. 1973;51(1):95–124. - PubMed
-
- Bass DM, Looman W, Ehrlich P. Predicting the Volume of Health and Social Services: Integrating Cognitive Impairment and the Modified Andersen Framework. The Gerontologist. 1992;32(1):33–43. - PubMed
-
- Duan N. Smearing Estimate: A Non-parametric Retransformation Method. Journal of the American Statistical Association. 1983;78(383):605–610.
-
- Ernst RL, Hay JW. Economic Research on Alzheimer Disease: a Review of the Literature. Alzheimer Disease and Associated Disorders. 1997;11(Suppl 6):135–45. - PubMed
-
- Evans DA, Scheer P, Cook N, et al. Estimated Prevalence of Alzheimer's Disease in the United States. Milbank Quarterly. 1990;68(2):267–89. - PubMed